Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jamie M Ellingford is active.

Publication


Featured researches published by Jamie M Ellingford.


Journal of Medical Genetics | 2016

Molecular findings from 537 individuals with inherited retinal disease

Jamie M Ellingford; Stephanie Barton; Sanjeev Bhaskar; James O'Sullivan; Simon G Williams; Janine A. Lamb; Binay Panda; Panagiotis I. Sergouniotis; Rachel L. Gillespie; Stephen P. Daiger; Georgina Hall; Theodora Gale; I. Christopher Lloyd; Paul N. Bishop; Simon C. Ramsden; Graeme C.M. Black

Background Inherited retinal diseases (IRDs) are a clinically and genetically heterogeneous set of disorders, for which diagnostic second-generation sequencing (next-generation sequencing, NGS) services have been developed worldwide. Methods We present the molecular findings of 537 individuals referred to a 105-gene diagnostic NGS test for IRDs. We assess the diagnostic yield, the spectrum of clinical referrals, the variant analysis burden and the genetic heterogeneity of IRD. We retrospectively analyse disease-causing variants, including an assessment of variant frequency in Exome Aggregation Consortium (ExAC). Results Individuals were referred from 10 clinically distinct classifications of IRD. Of the 4542 variants clinically analysed, we have reported 402 mutations as a cause or a potential cause of disease in 62 of the 105 genes surveyed. These variants account or likely account for the clinical diagnosis of IRD in 51% of the 537 referred individuals. 144 potentially disease-causing mutations were identified as novel at the time of clinical analysis, and we further demonstrate the segregation of known disease-causing variants among individuals with IRD. We show that clinically analysed variants indicated as rare in dbSNP and the Exome Variant Server remain rare in ExAC, and that genes discovered as a cause of IRD in the post-NGS era are rare causes of IRD in a population of clinically surveyed individuals. Conclusions Our findings illustrate the continued powerful utility of custom-gene panel diagnostic NGS tests for IRD in the clinic, but suggest clear future avenues for increasing diagnostic yields.


Ophthalmology | 2016

Whole Genome Sequencing Increases Molecular Diagnostic Yield Compared with Current Diagnostic Testing for Inherited Retinal Disease

Jamie M Ellingford; Stephanie Barton; Sanjeev Bhaskar; Simon G Williams; Panagiotis I. Sergouniotis; James O'Sullivan; Janine A. Lamb; Rahat Perveen; Georgina Hall; William G. Newman; Paul N. Bishop; Stephen A Roberts; Rick Leach; Rick Tearle; Stuart Bayliss; Simon C. Ramsden; Andrea H. Németh; Graeme C.M. Black

Purpose To compare the efficacy of whole genome sequencing (WGS) with targeted next-generation sequencing (NGS) in the diagnosis of inherited retinal disease (IRD). Design Case series. Participants A total of 562 patients diagnosed with IRD. Methods We performed a direct comparative analysis of current molecular diagnostics with WGS. We retrospectively reviewed the findings from a diagnostic NGS DNA test for 562 patients with IRD. A subset of 46 of 562 patients (encompassing potential clinical outcomes of diagnostic analysis) also underwent WGS, and we compared mutation detection rates and molecular diagnostic yields. In addition, we compared the sensitivity and specificity of the 2 techniques to identify known single nucleotide variants (SNVs) using 6 control samples with publically available genotype data. Main Outcome Measures Diagnostic yield of genomic testing. Results Across known disease-causing genes, targeted NGS and WGS achieved similar levels of sensitivity and specificity for SNV detection. However, WGS also identified 14 clinically relevant genetic variants through WGS that had not been identified by NGS diagnostic testing for the 46 individuals with IRD. These variants included large deletions and variants in noncoding regions of the genome. Identification of these variants confirmed a molecular diagnosis of IRD for 11 of the 33 individuals referred for WGS who had not obtained a molecular diagnosis through targeted NGS testing. Weighted estimates, accounting for population structure, suggest that WGS methods could result in an overall 29% (95% confidence interval, 15–45) uplift in diagnostic yield. Conclusions We show that WGS methods can detect disease-causing genetic variants missed by current NGS diagnostic methodologies for IRD and thereby demonstrate the clinical utility and additional value of WGS.


The Lancet | 2015

Pinpointing clinical diagnosis through whole exome sequencing to direct patient care: a case of Senior-Loken syndrome.

Jamie M Ellingford; Panagiotis I. Sergouniotis; Rachel Lennon; Sanjeev Bhaskar; Simon G Williams; Kate A Hillman; James O'Sullivan; Georgina Hall; Simon C. Ramsden; I. Christopher Lloyd; Adrian S. Woolf; Graeme C.M. Black

In 2002, a 2-month-old male infant was a ssessed by the general paediatric and paediatric ophthalmic services for roving eye movements and abnormal responses to visual cues. No concerns were raised about the child’s general health, but visual electrophysiology showed widespread photoreceptor cell dysfunction and retinal examination showed midperipheral fi ne pigment mottling and attenuation of retinal blood vessels (appendix). The child was diagnosed with non-syndromic infantile-onset retinal dystrophy, a common cause of visual impairment that is progressive and currently untreatable. The patient and his family have had regular follow-up and educational support and the family was referred for genetic counselling. In 2006, the proband’s younger sister presented with similar symptoms shortly after birth and we diagnosed the same condition (appendix).Genetic testing in retinal dystrophies has always been challenging because of the great genetic heterogeneity associated with these conditions. More than 20 genes have been linked with infantile-onset retinal dystrophy.


European Journal of Human Genetics | 2017

Validation of copy number variation analysis for next-generation sequencing diagnostics.

Jamie M Ellingford; Christopher Campbell; Stephanie Barton; Sanjeev Bhaskar; Saurabh Gupta; Rachel L Taylor; Panagiotis I. Sergouniotis; Bradley Horn; Janine A. Lamb; Michel Michaelides; Andrew R. Webster; William G. Newman; Binay Panda; Simon C. Ramsden; Graeme C.M. Black

Although a common cause of disease, copy number variants (CNVs) have not routinely been identified from next-generation sequencing (NGS) data in a clinical context. This study aimed to examine the sensitivity and specificity of a widely used software package, ExomeDepth, to identify CNVs from targeted NGS data sets. We benchmarked the accuracy of CNV detection using ExomeDepth v1.1.6 applied to targeted NGS data sets by comparison to CNV events detected through whole-genome sequencing for 25 individuals and determined the sensitivity and specificity of ExomeDepth applied to these targeted NGS data sets to be 100% and 99.8%, respectively. To define quality assurance metrics for CNV surveillance through ExomeDepth, we undertook simulation of single-exon (n=1000) and multiple-exon heterozygous deletion events (n=1749), determining a sensitivity of 97% (n=2749). We identified that the extent of sequencing coverage, the inter- and intra-sample variability in the depth of sequencing coverage and the composition of analysis regions are all important determinants of successful CNV surveillance through ExomeDepth. We then applied these quality assurance metrics during CNV surveillance for 140 individuals across 12 distinct clinical areas, encompassing over 500 potential rare disease diagnoses. All 140 individuals lacked molecular diagnoses after routine clinical NGS testing, and by application of ExomeDepth, we identified 17 CNVs contributing to the cause of a Mendelian disorder. Our findings support the integration of CNV detection using ExomeDepth v1.1.6 with routine targeted NGS diagnostic services for Mendelian disorders. Implementation of this strategy increases diagnostic yields and enhances clinical care.


American Journal of Medical Genetics Part A | 2016

Exploring the genetic basis of 3MC syndrome: Findings in 12 further families:

Jill Urquhart; Rebecca Roberts; Deepthi De Silva; Stavit A. Shalev; Elena Chervinsky; Sheela Nampoothiri; Yves Sznajer; Nicole Revencu; Romesh Gunasekera; Mohnish Suri; Jamie M Ellingford; Simon G Williams; Sanjeev Bhaskar; Jill Clayton-Smith

The 3MC syndromes are a group of rare autosomal recessive disorders where the main clinical features are cleft lip and palate, hypertelorism, highly arched eyebrows, caudal appendage, postnatal growth deficiency, and genitourinary tract anomalies. Ophthalmological abnormalities, most notably anterior chamber defects may also be seen. We describe the clinical and molecular findings in 13 individuals with suspected 3MC syndrome from 12 previously unreported families. The exclusion of the MASP1 and COLEC11 Loci in two individuals from different consanguineous families and the absence of mutations in four further individuals sequenced for both genes raises the possibility that that there is further genetic heterogeneity of 3MC syndrome.


Journal of Medical Genetics | 2018

Assessment of the incorporation of CNV surveillance into gene panel next-generation sequencing testing for inherited retinal diseases

Jamie M Ellingford; Bradley Horn; Christopher Campbell; Gavin Arno; Stephanie Barton; Catriona Tate; Sanjeev Bhaskar; Panagiotis I. Sergouniotis; Rachel L Taylor; Keren J. Carss; Lucy Raymond; Michel Michaelides; Simon C. Ramsden; Andrew R. Webster; Graeme C.M. Black

Background Diagnostic use of gene panel next-generation sequencing (NGS) techniques is commonplace for individuals with inherited retinal dystrophies (IRDs), a highly genetically heterogeneous group of disorders. However, these techniques have often failed to capture the complete spectrum of genomic variation causing IRD, including CNVs. This study assessed the applicability of introducing CNV surveillance into first-tier diagnostic gene panel NGS services for IRD. Methods Three read-depth algorithms were applied to gene panel NGS data sets for 550 referred individuals, and informatics strategies used for quality assurance and CNV filtering. CNV events were confirmed and reported to referring clinicians through an accredited diagnostic laboratory. Results We confirmed the presence of 33 deletions and 11 duplications, determining these findings to contribute to the confirmed or provisional molecular diagnosis of IRD for 25 individuals. We show that at least 7% of individuals referred for diagnostic testing for IRD have a CNV within genes relevant to their clinical diagnosis, and determined a positive predictive value of 79% for the employed CNV filtering techniques. Conclusion Incorporation of CNV analysis increases diagnostic yield of gene panel NGS diagnostic tests for IRD, increases clarity in diagnostic reporting and expands the spectrum of known disease-causing mutations.


Human Molecular Genetics | 2016

Mutations in the polyglutamylase gene TTLL5, expressed in photoreceptor cells and spermatozoa, are associated with cone-rod degeneration and reduced male fertility

Nicola Bedoni; Lonneke Haer-Wigman; Veronika Vaclavik; Viet H. Tran; Pietro Farinelli; Sara Balzano; Beryl Royer-Bertrand; Mohammed El-Asrag; Olivier Bonny; Christos Ikonomidis; Yan Litzistorf; Konstantinos Nikopoulos; Georgia G. Yioti; Maria Stefaniotou; Martin McKibbin; Adam P. Booth; Jamie M Ellingford; Graeme C.M. Black; Carmel Toomes; Chris F. Inglehearn; Carel B. Hoyng; Nathalie Bax; Caroline C. W. Klaver; Alberta A.H.J. Thiadens; Fabien Murisier; Daniel F. Schorderet; Manir Ali; Frans P.M. Cremers; Sten Andréasson; Francis L. Munier

Hereditary retinal degenerations encompass a group of genetic diseases characterized by extreme clinical variability. Following next-generation sequencing and autozygome-based screening of patients presenting with a peculiar, recessive form of cone-dominated retinopathy, we identified five homozygous variants [p.(Asp594fs), p.(Gln117*), p.(Met712fs), p.(Ile756Phe), and p.(Glu543Lys)] in the polyglutamylase-encoding gene TTLL5, in eight patients from six families. The two male patients carrying truncating TTLL5 variants also displayed a substantial reduction in sperm motility and infertility, whereas those carrying missense changes were fertile. Defects in this polyglutamylase in humans have recently been associated with cone photoreceptor dystrophy, while mouse models carrying truncating mutations in the same gene also display reduced fertility in male animals. We examined the expression levels of TTLL5 in various human tissues and determined that this gene has multiple viable isoforms, being highly expressed in testis and retina. In addition, antibodies against TTLL5 stained the basal body of photoreceptor cells in rat and the centrosome of the spermatozoon flagellum in humans, suggesting a common mechanism of action in these two cell types. Taken together, our data indicate that mutations in TTLL5 delineate a novel, allele-specific syndrome causing defects in two as yet pathogenically unrelated functions, reproduction and vision.


American Journal of Human Genetics | 2018

A dominantly inherited 5’UTR variant causing methylation associated silencing of BRCA1 as a cause of breast and ovarian cancer

D. Gareth Evans; Elke M. van Veen; Helen Byers; Andrew Wallace; Jamie M Ellingford; Glenda Beaman; Javier Santoyo-Lopez; Timothy J. Aitman; Diana Eccles; Fiona Lalloo; Miriam J. Smith; William G. Newman

Pathogenic variants in BRCA1 or BRCA2 are identified in ∼20% of families with multiple individuals affected by early-onset breast and/or ovarian cancer. Extensive searches for additional highly penetrant genes or alternative mutational mechanisms altering BRCA1 or BRCA2 have not explained the missing heritability. Here, we report a dominantly inherited 5′ UTR variant associated with epigenetic BRCA1 silencing due to promoter hypermethylation in two families affected by breast and ovarian cancer. BRCA1 promoter methylation of ten CpG dinucleotides in families who are affected by breast and/or ovarian cancer but do not have germline BRCA1 or BRCA2 pathogenic variants was assessed by pyrosequencing and clonal bisulfite sequencing. RNA and DNA sequencing of BRCA1 from lymphocytes was undertaken to establish allelic expression and the presence of germline variants. BRCA1 promoter hypermethylation was identified in 2 of 49 families in which multiple women are affected by grade 3 breast cancer or high-grade serous ovarian cancer. Soma-wide BRCA1 promoter hypermethylation was confirmed in blood, buccal mucosa, and hair follicles. Pyrosequencing showed that DNA was ∼50% methylated, consistent with the silencing of one allele, which was confirmed by clonal bisulfite sequencing. RNA sequencing revealed the allelic loss of BRCA1 expression in both families and that this loss of expression segregated with the heterozygous variant c.−107A>T in the BRCA1 5′ UTR. Our results establish a mechanism whereby familial breast and ovarian cancer is caused by an in cis 5′ UTR variant associated with epigenetic silencing of the BRCA1 promoter in two independent families. We propose that methylation analyses be undertaken to establish the frequency of this mechanism in families affected by early-onset breast and/or ovarian cancer without a BRCA1 or BRCA2 pathogenic variant.


Investigative Ophthalmology & Visual Science | 2017

Novel PEX11B Mutations Extend the Peroxisome Biogenesis Disorder 14B Phenotypic Spectrum and Underscore Congenital Cataract as an Early Feature

Rachel L Taylor; Mark T. Handley; Sarah Waller; Christopher Campbell; Jill Urquhart; Alison Meynert; Jamie M Ellingford; Deirdre E. Donnelly; Gisela Wilcox; I. Chris Lloyd; Helen Mundy; David Fitzpatrick; Charu Deshpande; Jill Clayton-Smith; Graeme C.M. Black

Purpose Peroxisomes perform complex metabolic and catabolic functions essential for normal growth and development. Mutations in 14 genes cause a spectrum of peroxisomal disease in humans. Most recently, PEX11B was associated with an atypical peroxisome biogenesis disorder (PBD) in a single individual. In this study, we identify further PEX11B cases and delineate associated phenotypes. Methods Probands from three families underwent next generation sequencing (NGS) for diagnosis of a multisystem developmental disorder. Autozygosity mapping was conducted in one affected sibling pair. ExomeDepth was used to identify copy number variants from NGS data and confirmed by dosage analysis. Biochemical profiling was used to investigate the metabolic signature of the condition. Results All patients presented with bilateral cataract at birth but the systemic phenotype was variable, including short stature, skeletal abnormalities, and dysmorphism—features not described in the original case. Next generation sequencing identified biallelic loss-of-function mutations in PEX11B as the underlying cause of disease in each case (PEX11B c.235C>T p.(Arg79Ter) homozygous; PEX11B c.136C>T p.(Arg46Ter) homozygous; PEX11B c.595C>T p.(Arg199Ter) heterozygous, PEX11B ex1-3 del heterozygous). Biochemical studies identified very low plasmalogens in one patient, whilst a mildly deranged very long chain fatty acid profile was found in another. Conclusions Our findings expand the phenotypic spectrum of the condition and underscore congenital cataract as the consistent primary presenting feature. We also find that biochemical measurements of peroxisome function may be disturbed in some cases. Furthermore, diagnosis by NGS is proficient and may circumvent the requirement for an invasive skin biopsy for disease identification from fibroblast cells.


Clinical and Experimental Ophthalmology | 2017

Next-generation sequencing targeted disease panel in rod-cone retinal dystrophies in Māori and Polynesian reveals novel changes and a common founder mutation

Andrea L. Vincent; Nandoun Abeysekera; Katherine van Bysterveldt; Verity F. Oliver; Jamie M Ellingford; Stephanie Barton; Graeme C.M. Black

This study identifies unique genetic variation observed in a cohort of Māori and Polynesian patients with rod‐cone retinal dystrophies using a targeted next‐generation sequencing retinal disease gene panel.

Collaboration


Dive into the Jamie M Ellingford's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sanjeev Bhaskar

Central Manchester University Hospitals NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Simon C. Ramsden

Central Manchester University Hospitals NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Stephanie Barton

Central Manchester University Hospitals NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Georgina Hall

Central Manchester University Hospitals NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge